On Monday, Harrow received an upgrade to its Relative Strength (RS) Rating, from 76 to 81.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
Harrow has moved more than 5% past a 20.31 entry in a third-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Harrow reported 0% earnings growth in its most recent report, while sales growth came in at 38%.
The company holds the No. 128 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
